ALSERES PHARMACEUTICALS INC /DE (ALSE) financial statements (2020 and earlier)

Company profile

Business Address 275 GROVE STREET
AUBURNDALE, MA 02466
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

6/30/2014
Q2
3/31/2014
Q1
12/31/2013
Q4
9/30/2013
Q3
6/30/2013
Q2
3/31/2013
Q1
12/31/2012
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments000000 
Cash and cash equivalents000000 
Short-term investments000000 
Prepaid expense and other current assets0 
Other undisclosed current assets00000  
Total current assets:000000 
Noncurrent Assets
Deferred costs000000 
Total noncurrent assets:000000 
TOTAL ASSETS:000000 
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:111222 
Other undisclosed accounts payable and accrued liabilities111222 
Debt   887 
Due to related parties111100 
Deferred revenue and credits000000 
Other liabilities000    
Other undisclosed current liabilities000    
Total current liabilities:222101010 
Noncurrent Liabilities
Long-term debt and lease obligation  8161616 
Long-term debt, excluding current maturities  8161616 
Liabilities, other than long-term debt111111 
Deferred revenue and credits111111 
Other liabilities000000 
Other undisclosed noncurrent liabilities88     
Total noncurrent liabilities:999171717 
Total liabilities:111111272727 
Stockholders' equity
Stockholders' equity attributable to parent, including:(11)(11)(11)(28)(27)(27) 
Common stock000000 
Additional paid in capital189189189172172172 
Accumulated other comprehensive income (loss)(0)(0)0(0)(0)(0) 
Retained earnings     0 
Other undisclosed stockholders' equity attributable to parent(200)(200)(200)(200)(200)(199) 
Other undisclosed stockholders' equity000000 
Total stockholders' equity:(11)(11)(10)(27)(27)(26) 
TOTAL LIABILITIES AND EQUITY:000000 

Income statement (P&L) ($ in millions)

6/30/2014
Q2
3/31/2014
Q1
12/31/2013
Q4
9/30/2013
Q3
6/30/2013
Q2
3/31/2013
Q1
12/31/2012
Q4
Gross profit:000000 
Operating expenses(0)(0)(2)0(0)(0) 
Other undisclosed operating income (loss)  1(1)   
Operating income (loss):(0)(0)0(0)(0)(0) 
Nonoperating income (expense) (0)10   
Investment income, nonoperating (0)     
Other nonoperating income   0   
Interest and debt expense(0)(0)  (0)(0) 
Other undisclosed loss from continuing operations before equity method investments, income taxes  (0)    
Net income (loss):(0)(0)1(0)(0)(0) 
Other undisclosed net income (loss) attributable to parent 0(0)(0)(0)(0) 
Net income (loss) available to common stockholders, diluted:(0)(0)0(0)(1)(0) 

Comprehensive Income ($ in millions)

6/30/2014
Q2
3/31/2014
Q1
12/31/2013
Q4
9/30/2013
Q3
6/30/2013
Q2
3/31/2013
Q1
12/31/2012
Q4
Net income (loss):(0)(0)1(0)(0)(0) 
Comprehensive income (loss):(0)(0)1(0)(0)(0) 
Other undisclosed comprehensive loss, net of tax, attributable to parent(0)(0)(0)(0)(0)  
Comprehensive income (loss), net of tax, attributable to parent:(0)(0)0(0)(0)(0) 

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: